Multicenter, double-blind, randomized, intra- individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in mri of brain tumors at 3 tesla

Journal of Magnetic Resonance Imaging

Volumn 29, Issue 4, 2009, Pages 760-767

  Rumboldt, Zoran ^a   Rowley, Howard A ^b   Steinberg, Fred ^c   Maldjian, Joseph A ^d   Ruscalleda, Jordi ^e   Gustafsson, Lars ^f   Bastianello, Stefano ^g  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UWHC Department of Radiology   (United States)

^c Univ MRI and Diagn Imaging Centers   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Brain tumor imaging; Comparative studies; Gadobenate dimeglu Mine; High field mri

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; EAR DISCOMFORT; FEMALE; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; NEUROIMAGING; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT; VOMITING; WILCOXON SIGNED RANKS TEST;

ADULT; AGED; BRAIN NEOPLASMS; CONTRAST MEDIA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; UNITED STATES;

EID: 65249130593     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21695     Document Type: Article

References (35)

1. MultiHance® (gadobenate dimeglumine injection). Package Insert. Princeton, NJ: Bracco Diagnostics.
2. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multi-center, intra-patient comparison of gado- benate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 2001;36:72-81.
3. Colosimo C, Knopp MV, Barreau X, et al. A comparison of Gd- BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 2004;46:655-665.
4. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55-64.
5. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389-400.
6. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intrain- dividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557-566.
7. Essig M, Tartaro A, Tartaglione T, Pirovano G, Kirchin MA, Spinazzi A. Enhancing lesions of the brain: intra-individual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 2006;13: 744-751.
8. Rowley HA, Scialfa G, Gao P-Y, et al. Contrast-enhanced MR imaging of brain lesions: a large scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008;29:1684-1691.
9. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213-221. Erratum in Invest Radiol 2006;41:859.
10. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40:715-724.
11. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gado- benate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol 2006;41: 244-248.
12. Criteria Committee of the American Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. New York: Little, Brown; 1994.
13. Kuhl CK, Traber F, Schild HH. Whole-body high-field-strength (3.0-T) MR Imaging in Clinical Practice. Part I. Technical considerations and clinical applications (review). Radiology 2008;246:675-696.
14. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol 1999;6:282-291.
15. Shellock FG, Parker JR, Venetianer C, Pirovano G, Spinazzi A. Safety of gadobenate dimeglumine: summary of findings from clinical studies and post-marketing surveillance. Invest Radiol 2006; 41:500-509.
16. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and inter- individual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 2006;24:1378-1385.
17. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003;14:426- 435.
18. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
19. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol 2006;41:222-228.
20. Trattnig S, Pinker K, Ba-Ssalamah A, Nobauer-Huhmann IM. The optimal use of contrast agents at high field MRI (review). Eur Radiol 2006;16:1280-1287.
21. Krautmacher C, Willinek WA, Tschampa HJ, et al. Brain tumors: full- and half-dose contrast-enhanced MR imagingat 3.0 Tcompared with 1.5 T-Initial Experience. Radiology 2005;237:1014-1019.
22. Ba-Ssalamah A, Nöbauer-Huhmann IM, Pinker K, et al. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases. Invest Radiol 2003;38:415-422.
23. Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR Am J Neuroradiol 2008;29: 668-673.
24. Yrjänä SK, Vaara T, Karttunen A, Koivukangas J. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths. Invest Radiol 2008;43:267-275.
25. Lupo JM, Lee MC, Han ET, et al. Feasibility of dynamic susceptibility contrast perfusion MR imaging at 3T using a standard quadrature head coil and eight-channel phased-array coil with and without SENSE reconstruction. J Magn Reson Imaging 2006;24: 520-529.
26. Mikulis DJ, Roberts TP. Neuro MR: protocols. J Magn Reson Imaging 2007;26:838-847.
27. Nöbauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 Tesla versus 1.5 Tesla. Invest Radiol 2002;37:114-119.
28. Yuh WT, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485-491.
29. Albert FK, Forsting M, Sartor K, et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994;34:45-60.
30. Warmuth-Metz M. Postoperative imaging after brain tumor resection. Acta Neurochir Suppl 2003;88:13-20.
31. Ciric I, Vick NA, Mikhael MA, et al. Aggressive surgery for malignant supratentorial gliomas. Clin Neurosurg 1990;36:375-383.
32. Ekinci G, Akpinar IN, Baltacioglu F, et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor re- growth and recurrence. Eur J Radiol 2003;45:99-107.
33. Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 2006;105:34-40.
34. Penfield JG, Reilly RF Jr. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007;3:654-668.
35. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-3178.